Saltz LB - Search Results

1

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Saltz LB, et al. J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930. J Clin Oncol. 2008. PMID: 18421054 Corrected and republished. Clinical Trial.

2

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Conti JA, et al. Among authors: saltz lb. Cancer. 1995 Feb 1;75(3):769-74. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. Cancer. 1995. PMID: 7828126 Clinical Trial.

3

A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.

Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP. Saltz LB, et al. Cancer. 1995 Feb 1;75(3):782-5. doi: 10.1002/1097-0142(19950201)75:3<782::aid-cncr2820750306>3.0.co;2-i. Cancer. 1995. PMID: 7828128 Clinical Trial.

4

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Conti JA, et al. Among authors: saltz lb. J Clin Oncol. 1996 Mar;14(3):709-15. doi: 10.1200/JCO.1996.14.3.709. J Clin Oncol. 1996. PMID: 8622015

5

Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy.

Tiersten A, Saltz LB. Tiersten A, et al. Among authors: saltz lb. J Clin Oncol. 1996 Jul;14(7):2043-6. doi: 10.1200/JCO.1996.14.7.2043. J Clin Oncol. 1996. PMID: 8683234

6

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Saltz LB, et al. J Clin Oncol. 1996 Nov;14(11):2959-67. doi: 10.1200/JCO.1996.14.11.2959. J Clin Oncol. 1996. PMID: 8918493 Clinical Trial.

7

Adjuvant treatment of colorectal cancer.

Saltz LB, Kelsen DP. Saltz LB, et al. Annu Rev Med. 1997;48:191-202. doi: 10.1146/annurev.med.48.1.191. Annu Rev Med. 1997. PMID: 9046955 Review.

8

A phase II study of topotecan administered five times daily in patients with advanced gastric cancer.

Saltz LB, Schwartz GK, Ilson DH, Quan V, Kelsen DP. Saltz LB, et al. Am J Clin Oncol. 1997 Dec;20(6):621-5. doi: 10.1097/00000421-199712000-00018. Am J Clin Oncol. 1997. PMID: 9391553 Clinical Trial.

9

Irinotecan in the first-line treatment of colorectal cancer.

Saltz LB. Saltz LB. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):54-8. Oncology (Williston Park). 1998. PMID: 9726092 Review.

10

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D. Saltz LB, et al. J Clin Oncol. 1998 Dec;16(12):3858-65. doi: 10.1200/JCO.1998.16.12.3858. J Clin Oncol. 1998. PMID: 9850031 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

414 results

Search Page